ArticleCureus2025
Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetes mellitus (T2DM) is a chronic disease that substantially increases morbidity and mortality through its cardiovascular and renal complications. Beyond mere glycemic control, current guidelines from the European Society of Cardiology (ESC) and Kidney Disease: Improving Global Outcomes (KDIGO) recommend interventions that confer additional cardiovascular and renal benefits.
objectiveThis study aims to assess and compare the efficacy of semaglutide versus empagliflozin in improving glycemic control, weight, blood pressure, and renal function in patients with uncontrolled T2DM after 18 months of follow-up.
methodsThis retrospective cohort study included 41 patients with uncontrolled T2DM (glycated hemoglobin (HbA1c) > 7%) who received either empagliflozin (n=20) or semaglutide (n=21) as monotherapy. Clinical and laboratory parameters (HbA1c, fasting plasma glucose, body weight, systolic and diastolic blood pressure, serum creatinine, estimated glomerular filtration rate (eGFR), and urine microalbumin) were measured at baseline and 18 months (SEMPA18). Changes were compared between the two groups using appropriate statistical methods.
resultsOf the 41 participants (58.5% male), 20 were treated with empagliflozin and 21 with semaglutide. After 18 months, median HbA1c decreased from 7.60% to 6.85% in the empagliflozin group (100% improved) and from 7.90% to 7.00% in the semaglutide group (95.2% improved). A reduction in body weight of 5% or more was achieved by 2 of 20 (10.0%) empagliflozin-treated patients versus 6 of 21 (28.6%) among those on semaglutide (p=0.48). Albuminuria improved in 18 of 20 (90.0%) empagliflozin users (median final: 12.0 mg/dL) compared to 14 of 21 (66.7%) semaglutide users (median final: 20.0 mg/dL), although the difference was not statistically significant (p=0.07). Both groups showed gains in eGFR (final median: 80.50 vs. 71.00 mL/min/1.73 m²; p=0.048), and serum creatinine decreased in the majority of patients (75.0% vs. 71.4%). A subgroup analysis revealed that heart failure status (LVEF < 50% or documented diagnosis) was associated with less improvement in renal markers, particularly serum creatinine, regardless of the treatment group.
conclusionsIn this real-world, 18-month cohort, empagliflozin produced more pronounced improvements in albuminuria and a slightly greater absolute reduction in HbA1c, whereas semaglutide showed a trend toward greater weight loss, though not statistically significant. These findings emphasize individualized therapy choices in T2DM based on cardiorenal risk profiles and underscore the potential value of early empagliflozin initiation, especially in patients at higher risk of renal deterioration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.